Faculty Summaries
Dr. Ross
Eric A. Ross, PhD
Associate Research Professor
  • Assistant Vice President of Biometrics and Information Sciences
  • Director,
  • Director,
Lab Phone: 215-728-2891
Fax: 215-728-2553
Office: R383
Research Interests

Our research focuses on the innovative use of quantitative methods and information technology in cancer research. Our statistical methodology research includes development and application of novel methods for the analysis of correlated failure time and high throughput laboratory data. We are also interested in the creation of new randomized Phase II clinical trial designs that permit early stopping in both patient number and time of initial evaluation. These designs provide for early termination for futility or efficacy, and should be particularly appropriate for studies in patient populations with a high likelihood for rapid disease progression. Our collaborations with numerous investigators conducting clinical, translational, cancer control, epidemiology, and basic science research rigorously extend the quantitative interpretation of results from these disciplines. Our informatics research facilitates cancer investigations by promoting the use of computer-based methods that improve research efficiency and data quality. Special areas of interest include large-scale data integration, and the development and application of web-based technologies to enable remote data collection/presentation, health education and new interventions.  

Selected Publications

Fox Chase Programs

  1. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst. 1994 Apr 20;86(8):620-5. PubMed
  2. Ross EA, Moore D. Modeling clustered, discrete or grouped-time survival data with covariates. Biometrics. 1999 Sep;55(3):813-9. PubMed
  3. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight year follow-up of the 90,000 person Haimen City Cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):369-76. PubMed
  4. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7. PubMed
  5. Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila). 2010 Jan;3(1):48-61. PubMed
  6. Ariazi, E.A., Cunliffe, H., Lewis-Wambi, J., Slifker, S., Willis, A., Ramos, P., Tapia, P., Kim, H., Yerrum, S., Sharma, C., Nicolas, E., Balagurunathan, Y., Ross, E.A., Jordan, V.C., Estrogen-induces apoptosis in estrogen deprivation-resistant breast cancer via stress responses as identified by global gene expression. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18879-86. PubMed
All publications